DiscoverLife Science TodayNovo + Forma, Sanofi, Boehringer Ingelheim, Arcturus
Novo + Forma, Sanofi, Boehringer Ingelheim, Arcturus

Novo + Forma, Sanofi, Boehringer Ingelheim, Arcturus

Update: 2022-09-06
Share

Description

A $1.1B acquisition, two FDA approvals, and grants for mRNA vaccines. 

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Novo + Forma
Sanofi
Boehringer Ingelheim
Arcturus


About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Novo + Forma, Sanofi, Boehringer Ingelheim, Arcturus

Novo + Forma, Sanofi, Boehringer Ingelheim, Arcturus

Noah Goodson, PhD